Elevated CA125 is associated with incident heart failure and increased mortality in patients with acute coronary syndrome

Research output: Contribution to journalPublished meeting abstract

Abstract

Background: Carbohydrate antigen 125 (CA125) is a mucin produced by serosal cells in response to mechanical and inflammatory stimuli. CA125 has emerged as prognostic biomarker in heart failure (HF) and correlates with markers of fluid overload, echocardiographic parameters and prognosis in HF patients. In patients with acute coronary syndrome (ACS), elevated CA125 is correlated with a higher risk of in-hospital HF. The relationship between CA125 and long-term prognosis in ACS patients has not previously been assessed. Purpose: The purpose of our study was to investigate if CA125 measured at the time of an acute coronary event is related to cardiac remodeling during the first year of follow-up and long-term risk for HF and death Methods: We measured CA125 in plasma within 24 hours of the acute event in 523 patients with acute myocardial infarction or unstable angina admitted to the Coronary Care Unit. Routine echocardiograms were performed in all participants. The primary outcomes were hospitalization with a diagnosis of heart failure or death during follow-up, identified through data from the Swedish Hospital Discharge Register and the Swedish Cause of Death Register. In a subgroup of 109 patients aged 75 years or above we assessed the relationships between baseline CA125 and echocardiographical parameters of cardiac structure and function at 1 year after the index ACS. Results: The median follow-up period was 27.3 months for incident HF and 39.5 months for mortality. In Cox proportional hazards models we found an adjusted hazard ratio of 1.51 (95% CI 1.08-2.12; p

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cardiac and Cardiovascular Systems

Keywords

  • acetylsalicylic acid, amino terminal pro brain natriuretic peptide, angiotensin receptor antagonist, beta adrenergic receptor blocking agent, biological marker, CA 125 antigen, cystatin C, dipeptidyl carboxypeptidase, endogenous compound, high density lipoprotein, hydroxymethylglutaryl coenzyme A reductase inhibitor, low density lipoprotein, purinergic P2Y12 receptor, triacylglycerol, troponin T, acute coronary syndrome, acute heart infarction, aged, cause of death, coronary care unit, diabetes mellitus, diagnosis, echocardiography, female, follow up, gender, hazard ratio, heart development, heart left atrium, heart left ventricle ejection fraction, hospital discharge, hospitalization, human, human tissue, hypertension, major clinical study, male, plasma, prognosis, proportional hazards model, smoking, structure activity relation, systolic dysfunction, thrombocyte, unstable angina pectoris
Original languageEnglish
Pages (from-to)1392-1393
JournalEuropean Heart Journal
Volume37
Issue numberSuppl 1
Publication statusPublished - 2016 Aug 1
Publication categoryResearch
Peer-reviewedNo
EventESC Congress 2016 - Rome, Italy
Duration: 2016 Aug 272016 Aug 31